NEW ORLEANS (EGMN) - The investigational agent INCB18424 provides sustained relief in patients with myelofibrosis, a disease with no approved therapies and an average life expectancy of 5-7 years.Individually optimized doses of the oral janus-associated kinase (JAK) inhibitor resulted in rapid and durable responses with an improved hematologic safety profile in 153 patients, the lead author, Dr. Srdan Verstovsek, reported at the annual meeting of the American Society of Hematology (ASH)."This medication...